The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura

Journal of Clinical Apheresis

Volumn 28, Issue 6, 2013, Pages 416-421

  O'Brien, Kerry L ^a   Price, Thomas H ^a,b   Howell, Camille ^a   Delaney, Meghan ^a,b  

^a PUGET SOUND BLOOD CENTER   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

albumin; fluid; plasma exchange; replacement; thrombocytopenic purpura

Indexed keywords

ALBUMIN; IMMUNOGLOBULIN; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ADVERSE OUTCOME; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; FEMALE; HUMAN; MALE; PLASMAPHERESIS; RELAPSE; REMISSION; RESPONSE TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ALBUMIN; FLUID; PLASMA EXCHANGE; REPLACEMENT; THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MALE; MIDDLE AGED; PLASMA; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SOLUTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889690065     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21288     Document Type: Article

References (22)

1. Moschcowitz E,. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Proc N Y Pathol Soc 1924; 24: 21-24. Reprinted in: Mt Sinai J Med 2003;70:352-355.
2. McLeod BC, Weinstein R, Winters JL, Szczepiorkowski ZM, editors. Apheresis: Principles and Practice, 3rd ed. Bethesda MD: AABB Press; 2010.
3. George JN, Terrell DR, Swisher KK, Vesely SK,. Lessons learned from the Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry. J Clin Apheresis 2008; 23: 129-137.
4. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE,. Effect of plasma exchange on plasma ADAMTS13 metalloproteinase activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
5. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-397.
6. Frawley N, Ng AP, Nicholls K, Cohney S, Hogan C, Grigg A,. Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single centre experience. Int Med J 2009; 38: 19-24.
7. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis 2010; 25; 83-177.
8. Fontana S, Kremer Hovinga JA, Lammle B, Mansouri Taleghani B,. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006; 90: 245-254.
9. Linenberger ML, Price TH,. Use of cellular and plasma apheresis in the critically ill patient. II. Clinical indications and applications. J Intensive Care Med 2005; 20: 88-103.
10. Altuntas F, Aydogdu I, Kabukcu S, Kocyigit I, Cikim K, Sari I, Erkut MA, Eser B, Ozturk A, Kaya E, Cetin M, Keskin A, Unal A,. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: A retrospective multicenter study. Transfus Apheresis Sci 2007; 36: 57-67.
11. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F,. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009; 7: 1703-1710.
12. Brecher ME, Hay SN, Park YA,. Theoretical efficacy of using albumin/plasma versus full plasma replacement in TTP. J Clin Apheresis 2011; 26: 58.
13. Bandarenko N, Brecher ME, members of the US TTP Apheresis Study Group. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group: multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis 1998; 13: 133-141.
14. Brecher ME,. Plasma exchange: why we do what we do. J Clin Apheresis 2002; 17: 207-211.
15. Brailey LL, Brecher ME, Bandarenko N,. Apheresis and the thrombotic thrombocytopenic purpura syndrome: current advances in diagnosis, pathophysiology, and management. Ther Apheresis 1999; 3: 20-24.
16. Bell WR, Braine HG, Ness PM, Kickler TS,. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403.
17. Fontana S, Kremer Hovinga JA, Studt JD, Alberio L, Lammle B, Mansouri Taleghani B,. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol 2004; 41: 48-59.
18. Zhan H, Streiff MB, King KE, Segal JB,. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992-2008: clinical outcomes and risk factors for relapse. Transfusion 2010; 50: 868-874.
19. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN,. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511.
20. Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF,. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007; 17: 17-35.
21. George JN,. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
22. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N,. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apheresis 2001; 16: 134-138.